A Paradigm Shift in Cancer Treatment

The field of oncological radiotherapy is rapidly evolving, offering a technologically advanced and cost-effective approach to cancer treatment. radiotherapy is currently used in approximately 60% of new cancer cases, either as a standalone treatment or in conjunction wiht systemic therapies. The latest research indicates that reducing the duration of radiotherapy does not compromise its effectiveness and can substantially enhance patients’ well-being.

The results that emerged represent a potential change of paradigm in the treatment of some tumors thanks to radiotherapy. The reduced regime, shorter and well tolerated, is configured as a new therapeutic option, with clinical and organizational benefits for patients, caregivers, families and health systems.These studies change clinical practice towards shorter, effective and enduring treatments.

Prof. Marco Krengli, president of Airo

According to Professor Krengli, president of Airo, these shorter, well-tolerated regimens represent a new therapeutic avenue with clinical and organizational advantages for patients, caregivers, families, and healthcare systems. This shift towards shorter, effective, and sustainable treatments has significant implications for patient health, allowing them to return to their daily lives more quickly. It also benefits the healthcare system by reducing costs and optimizing resource allocation, perhaps alleviating waiting lists.

Specific Cancer Studies: Prostate, Breast, and Anal Cancers

Several key studies presented at the congress highlighted the effectiveness of shorter radiotherapy treatments for specific cancers:

Prostate Cancer

A study involving over 1,200 men with intermediate and high-risk prostate cancer demonstrated that a 2.5-week radiotherapy course was as effective as the standard 8-week treatment in terms of cancer control and toxicity. These findings, collected over a 10-year follow-up period, suggest a significant prospect to reduce treatment duration without compromising outcomes.

Breast Cancer

Research on breast cancer patients revealed comparable results between a 5-day radiotherapy regimen and the conventional 15-session approach. After 10 years, no significant differences were observed, indicating that shorter treatments can be just as effective in managing breast cancer.

Anal Cancer

A groundbreaking study published in The Lancet Oncology challenged the standard dose in radiochemotherapy for early-stage anal cancer.The data suggest that intensity-modulated radiotherapy with a reduced dose can offer comparable, and in some cases superior, loco-regional control rates compared to standard treatment. Importantly, the reduced dose also resulted in fewer long-term side effects and improved recovery of functions affected by radiotherapy.

The Growing Demand for radiotherapy and the Need for Investment

With radiotherapy indicated in 60% of new cancer cases, the demand for this treatment modality is steadily increasing. However, in Italy, there is a pressing need to modernize and expand the radiotherapy machine park. The technology is rapidly advancing, and the role of the radiotherapist within the care team is becoming increasingly crucial.

Experts estimate that the machine park needs to expand by at least 20% to meet the rising demand, which is projected to increase by 15% by 2025. This expansion would enable the treatment of an additional one million people and potentially save countless lives. Investment in radiotherapy infrastructure is essential to ensure that patients have access to the most effective and efficient cancer treatments available.